Against all reluctance, NGS has proved itself to be extremely useful in the study and diagnosis of MM, aiding in the discovery of several novel genomic markers, such as genetic loci rs12521798 and rs17748074 linked to bortezomib-induced peripheral neuropathy in MM patients [58]; glutathione-s-transferase (GST) polymorphisms and tumor necrosis factor-α (TNF-α) associated with the survival in MM [59]; polymorphism rs4240803 of SLC7A45 linked to a better response in MM patients with melphalan based therapy [60]; and hypodiploidy or hyperploidy associated with a poor prognosis in MM [61,62]. This evidence concerns the gene HPGDS and Miyoshi myopathy.